Cronex Co., Ltd.
KKRX:215570598.00
KRW
+43.00
(+7.75%)
ISIN
KR7215570003
Return %
Stock
S&P 500
1Y
-36.72
14.20
3Y
-50.17
81.12
5Y
-88.16
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 26
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Hwaseong-si South Korea
- IPO Date
- Dec 22, 2015
- Website
- cronex.co.kr
- Similar Companies
- Business
- Cronex Co., Ltd. is a South Korea-based biotechnology and non-clinical contract research organization specializing in the breeding of specific pathogen-free miniature pigs, preclinical testing services, xenotransplantation research, and porcine-derived biomaterials. Founded in 2012 and headquartered in Cheongju, Chungcheongbuk-do, South Korea, the company operates within the life sciences, medical technology, and biopharmaceutical sectors. Cronex provides specialized research models, translational testing, and biological materials to pharmaceutical corporations, biotechnology enterprises, academic institutions, and medical research hospitals in South Korea and international markets. The company offers a comprehensive portfolio of products and services organized into several core business segments, which include: Specific Pathogen-Free and Transgenic Research Animals, consisting of laboratory-grade micropigs and genetically engineered swine developed for pharmacological evaluations, surgical modeling, biocompatibility assessments, and xenotransplantation studies; Non-Clinical Contract Research Organization Services, encompassing in vivo pharmacokinetic and pharmacodynamic testing, toxicological evaluations, efficacy screening, medical device implant safety testing, and customized surgical disease modeling; Porcine-Derived Medical Biomaterials, comprising medical-grade atelocollagen, extracellular matrix scaffolds, and tissue engineering matrices extracted from pathogen-free miniature pigs for wound healing dressings, orthopedic repair, dental regeneration, and aesthetic medicine; Veterinary Diagnostic Solutions, featuring point-of-care rapid testing kits, diagnostic reagents, and analytical screening systems for infectious diseases in livestock and companion animals; and Preclinical Facility Services, providing animal housing, barrier cleanroom environments, surgical suites, and specialized imaging services for biomedical investigators. In recent developments, Cronex Co., Ltd. has expanded its regenerative biomaterials operations and advanced its non-clinical research capabilities. The company has established strategic research collaborations with biopharmaceutical companies and academic medical centers to advance xenotransplantation programs, focusing on porcine pancreatic islet and corneal tissue transplantation. To address growing demand for non-clinical evaluation of cell and gene therapies and advanced implantable medical devices, Cronex has enhanced its testing facilities and upgraded operational procedures in accordance with Good Laboratory Practice standards. Furthermore, the company has commercialized high-purity medical-grade collagen formulations targeted at aesthetic dermatology and surgical wound care, broadened its line of veterinary diagnostic assays, and executed strategic initiatives to secure capital investment aimed at scaling laboratory infrastructure and supporting a future transfer listing from the KONEX market to the KOSDAQ exchange.